Hypertension in pregnancy Pregnancy and Childbirth
Conditions
Interventions
The intervention is daily self-monitoring of blood pressure with weekly urine protein testing, recorded using a multi-component app. Depending on self-monitoring blood pressure readings a 1-step titra
Sponsors
University of Oxford
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Pregnant women aged 18 years to 60 years 3. Diagnosis of hypertension (blood pressure previously sustained at =140/90mmHg) 4. From 20 weeks (+/-4 weeks) gestation, up to 34 weeks gestation 5. Currently prescribed one antihypertensive medication 6. Currently negative protein on urine dipstick testing
Exclusion criteria
Exclusion criteria: 1. Women whom the midwife or obstetrician feels that it would be inappropriate to approach, for example, those acutely unwell 2. Participant does not wish to self-monitor / self-manage their blood pressure 3. Abnormal uterine artery Doppler results in this pregnancy 4. Early onset (<34 weeks gestation) pre-eclampsia in a previous pregnancy 5. Imminent delivery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following primary outcome measures will be assessed: 1. The recruitment rate per site (number approach versus number recruited) measured using data recorded in the My Pregnancy Care app at the end of the recruitment period 2. Adherence and persistence to the self-monitoring protocol (number of readings submitted versus the number of readings that the protocol requests) measured using data recorded in the My Pregnancy Care app at the time point of delivery of the baby 3. Adherence and persistence to self-testing for proteinuria (number of readings submitted versus the number of readings that the protocol requests) measured using data recorded in the My Pregnancy Care app at the time point of delivery of the baby 4. Loss to follow-up measured using data recorded in My Pregnancy Care at the end of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Systolic blood pressure between groups measured using a sphygmomanometer device at the end of the study 2. Serious adverse events and side effects and the number of adverse events measured using data collected in the study records at the end of the study | — |
Countries
England, United Kingdom
Contacts
Public ContactKatherine Tucker
Outcome results
None listed